The Research Animal Support Facility (RASF) exists to support ongoing research involving laboratory animals at MD Anderson. All animal facilities are accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care International, have Animal Welfare Assurance approval, and are registered as research animal facilities with the US Department of Agriculture. The RASF has two locations: RASF-Houston (RASF-H -112,990 ft^) and RASF-Smithville (RASF-S -30,000 ft^). Both RASF facilities provide housing, procedure space, veterinary care, and quality assurance programs for animals used in cancer research. Clinical, surgical, imaging, radiation therapy, and pathology laboratory facilities and services such as Genetic Services and Mutant Mouse Pathology Service are also provided. RASF-H veterinarians provide consultation services and participate in all relevant compliance committees. Major equipment includes individually ventilated rodent caging, automated bedding dispensing and waste collection, patient monitoring in vivo imaging systems, automated pathology specimen processing, and vehicles for materials animal transport. The RASF has 156 personnel, including 17 veterinarians and 97 animal care personnel. In the past 5 years, the RASF has been used by 378 investigators supporting all 19 CCSG programs. Publications cited using the RASF have appeared in several high impact journals such as Nature, Nature Med, Cell Stem Cell and PNAS. Peer-reviewed investigators represent 92% of the RASF-H and 95% of RASF-S user utilization. The RASF-H requests 5% of CCSG support for the next grant cycle, and 26.5% for RASF-S. User fees account for 52% (RASF-H) and 44% (RASF-S), institutional support is 43% (RASF-H) and 23% (RASF-S), and 2% other sources support RASF-S. FIASF-H. Future plans include renovation and expansion of the CRB basement animal facility, build-out of the animal imaging support holding facility on South Campus, and upgrading and implementing computer applications for business operations and preclinical drug development. RASF-S future plans include enhancing/expanding barrier facilities, continued customization of breeding colony management software, development of new research genetic services and new ante-mortem bioluminescence and fluorescence imaging services.

Public Health Relevance

The RASF's purpose is to provide the highest quality animal care and support for animal research by delivering a wide range of cost-efficient veterinary services, including specialized genetic services and mutant mouse pathology services. Such services are essential for the conduct of cutting-edge research aimed at improving cancer prevention and treatment with the ultimate goal of eliminating cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016672-38
Application #
8557369
Study Section
Subcommittee G - Education (NCI)
Project Start
1998-09-04
Project End
2018-06-30
Budget Start
2013-09-06
Budget End
2014-06-30
Support Year
38
Fiscal Year
2013
Total Cost
$1,152,622
Indirect Cost
$432,374
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Tayob, Nabihah; Richardson, Peter; White, Donna L et al. (2018) Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System. BMC Med Res Methodol 18:1
Caruso, Joseph A; Duong, Mylinh T; Carey, Jason P W et al. (2018) Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies. Cancer Res 78:5481-5491
Yu, Wangie; Chen, Yunyun; Dubrulle, Julien et al. (2018) Cisplatin generates oxidative stress which is accompanied by rapid shifts in central carbon metabolism. Sci Rep 8:4306
Tanco, Kimberson; Azhar, Ahsan; Rhondali, Wadih et al. (2018) The Effect of Message Content and Clinical Outcome on Patients' Perception of Physician Compassion: A Randomized Controlled Trial. Oncologist 23:375-382
Elimova, Elena; Wang, Xuemei; Qiao, Wei et al. (2018) Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. Oncology 94:345-353
Hoadley, Katherine A; Yau, Christina; Hinoue, Toshinori et al. (2018) Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell 173:291-304.e6
Ma, Jiacheng; Huo, XiaoJiao; Jarpe, Matthew B et al. (2018) Pharmacological inhibition of HDAC6 reverses cognitive impairment and tau pathology as a result of cisplatin treatment. Acta Neuropathol Commun 6:103
Meisel, Jane; Zhang, Chao; Neely, Cameron et al. (2018) Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score. Clin Breast Cancer 18:347-352
Williams, Patrick; Basu, Sreyashi; Garcia-Manero, Guillermo et al. (2018) The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer :
Koyyalagunta, Dhanalakshmi; Bruera, Eduardo; Engle, Mitchell P et al. (2018) Compliance with Opioid Therapy: Distinguishing Clinical Characteristics and Demographics Among Patients with Cancer Pain. Pain Med 19:1469-1477

Showing the most recent 10 out of 12418 publications